Rimonabant (168273-06-1) is a selective CB1 receptor inverse agonist (Ki = 1.8 nM).1,2 It is an anorectic antiobesity drug originally approved for use in Europe but eventually withdrawn from the market because of potential severe psychiatric side effects.
1) Rinaldi-Carmona et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor; FEBS Lett. 350 240
2) Rinaldi-Carmona et al. (1995) Biochemical and pharmacological characterization of SR141716A, the first potent and selective cannabinoid receptor antagonist; Life Sci. 56 1941